News
Memorial Sloan Kettering Cancer Center Research Shows How Realyze Intelligence Solves the Scalability Problem of Manual Curation
A poster, presented today, Thursday, April 9, 2024, at the American Association for Cancer Research Annual Meeting, (AACR Annual Meeting) demonstrated that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) successfully applied machine learning (ML) and large language models (LLM) to augment the manual curation of cancer data elements using the Realyze Intelligence platform.
Realyze Intelligence Named to CancerX Accelerator Inaugural Class
Realyze Intelligence has earned a position among the inaugural class of start-up companies selected for the CancerX Startup Accelerator, part of the Biden administration Cancer Moonshot program that aims to cut the U.S. cancer death rate in half within the next 25 years.
Realyze Joins Creative Destruction Lab’s Cancer Program Cohort to “Create Something Massive” in 2024
Realyze Intelligence is honored to announce that they have been selected by the Creative Destruction Lab (CDL) to join their current cancer program cohort.
Realyze Strengthens Board and Advisory Panel with Industry Experts
Realyze Intelligence is thrilled to share that Michael Finke and Scot Stevens have joined the company’s Board of Directors and that Carolyn Penstein Rose, PhD, will be working with the company as an Advisor.
New Report: Optimizing Clinical Trials at Health Systems
Matching patients to clinical trials could be improved with an artificial intelligence (AI) solution that allows health systems to identify participants more quickly and easily, according to new research from the Center for Connected Medicine (CCM). Report available to download.
Realyze Intelligence Collaborating with Leading Cancer Center to Gain Insight into Patient Phenotypic Data
Realyze Intelligence’s solution is now being used at Memorial Sloan Kettering Cancer Center’s Innovation Hub to unlock clinical data and improve cancer treatment.